A clinical randomized control trial of Yangxinkang Tablets for chronic heart failure

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000549

Enrollment

Unknown

Registered

2009-09-17

Start date

2008-01-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Dysfunction

Interventions

Group B:Placebo 3 pills, three times a day on the basis of routine treatment

Group A:Yangxinkang tablets3 pills three times a day on the basis of routine treatment

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Male or female patients aged 18 to 75 years old whose diagnosis was chronic heart failure and NYHA grade was II-III.

Exclusion criteria

Exclusion criteria: 1. Patients with serious dysfunction of lung, liver or kidney; 2. Patients with serious cardiac arrhythmias.

Design outcomes

Primary

Measure	Time frame
Heart function grade;	—

Secondary

Measure	Time frame
Improvement of clinical symptoms;Quality of Life;	—

Countries

China

Contacts

Public ContactShaoxiang Xian

xianshaoxiang@yahoo.com.cn+86 020 36591692

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026